Signum Dermalogix

Signum Dermalogix, a spin out of Signum Biosciences, is a private biotech company founded in 2011 from technologies developed by Dr. Jeffry Stock at Princeton University. We develop cosmetic functional ingredients as well as topical drug candidates for dermatological disease. Our main research focus is to produce novel chemical entities and botanic... al extracts for skin care by performing robust screening assays in our labs. In addition we provide in vitro and in vivo assay systems and robust analytical expertise including safety, efficacy and claim substantiation for cosmetics, botanicals, nutraceuticals and pharmaceuticals. We specialize in producing customized cosmetic claim support and/or efficacy tests providing robust scientific data to support advertising or packaging claims. Signum Biosciences is focused on cutting edge research in neurodegeneration, while Signum Dermalogix provides innovation in cosmetics, therapeutic dermatology and testing services. We are a company focused on the discovery and development of innovative products to address major medical needs in the field of dermatology.Signum Dermalogix develops synthetic compounds that are mimetics of natural lipid ligands crucial to cellular regulation and signaling.These proprietary New Chemical Entities (NCEs) have significant pharmaceutical potential for treating regulatory dysfunctions underlying inflammatory skin diseases such as Acne, Atopic Dermatitis, Psoriasis, and Rosacea.Read More